Literature DB >> 8194046

Cytogenetic studies, ras mutation, and clinical characteristics in primary myelodysplastic syndrome. A study on 68 Chinese patients in Taiwan.

H F Tien1, C H Wang, S M Chuang, J M Chow, F Y Lee, M C Liu, Y C Chen, M C Shen, D T Lin, K H Lin.   

Abstract

Cytogenetics and clinical features were studied for 68 Chinese patients with primary myelodysplastic syndrome (MDS). Ras mutation was analyzed in 25 of them. Thirty-four patients (50%) had clonal chromosomal abnormalities at initial analysis. The most common cytogenetic aberrations were -7, +8, 5q-, and 20q-, which occurred in 11 (16.2%), seven (10.3%), five (7.4%) and three patients, respectively. The incidence of -7 was higher and that of 5q- lower in our patients than in patients from most other geographic areas. The 17 patients with multiple chromosomal abnormalities had a significantly shorter median survival (9 months) than the 34 patients with normal karyotype (33 months) and the 17 patients with patients with single anomalies (26 months). Evolution to acute leukemia occurred in 20 patients (29%) after a median interval of 8 months following the diagnosis. Patients with multiple cytogenetic changes at initial analysis or in subsequent studies had a significantly higher frequency of acute transformation than others (55% vs. 18.6%, p = 0.007); the same was not true if only the data of initial study were considered. Serial cytogenetic studies are important in patient follow-up. N-ras mutation was detected in 5 (20%) of 25 patients within the study. There was no correlation between the gene mutation and acute transformation. But combing the data of N-ras mutation and cytogenetics, patients with either the N-ras mutation or clonal chromosomal abnormalities were at significantly higher risk for developing acute leukemia than those with neither of the changes (77% vs. 25%).

Entities:  

Mesh:

Year:  1994        PMID: 8194046     DOI: 10.1016/0165-4608(94)90027-2

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  5 in total

1.  High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes.

Authors:  Christine L O'Keefe; Ramon Tiu; Lukasz P Gondek; Jennifer Powers; Karl S Theil; Matt Kalaycio; Alan Lichtin; Mikkael A Sekeres; Jaroslaw P Maciejewski
Journal:  Exp Hematol       Date:  2007-02       Impact factor: 3.084

Review 2.  The molecular genetics of hematologic malignancies.

Authors:  A Bagg
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

3.  First Cytogenetic Profile of Omani Patients with de novo Myelodysplastic Syndromes: Comparison with data from Asia, Africa, Europe and North and South America.

Authors:  Achandira M Udayakumar; Nagla Fawaz; Anil Pathare; Shakila Asraf; Mohammed Al-Huneini; Khalil Al-Farsi; Salam Al-Kindi; Murtadha Al-Khabouri
Journal:  Sultan Qaboos Univ Med J       Date:  2017-10-10

4.  Distinct association between aberrant methylation of Wnt inhibitors and genetic alterations in acute myeloid leukaemia.

Authors:  H-A Hou; Y-Y Kuo; C-Y Liu; M C Lee; J-L Tang; C-Y Chen; W-C Chou; C-F Huang; F-Y Lee; M-C Liu; M Yao; H-F Tien
Journal:  Br J Cancer       Date:  2011-11-17       Impact factor: 7.640

5.  Phenotypic and Cytogenetic Characterization of Mesenchymal Stromal Cells in De Novo Myelodysplastic Syndromes.

Authors:  A J I S Rathnayake; H W W Goonasekera; V H W Dissanayake
Journal:  Anal Cell Pathol (Amst)       Date:  2016-08-29       Impact factor: 2.916

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.